when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BRISTOL MYERS SQUIBB · news · pharmadog

← back to BRISTOL MYERS SQUIBB

News mentioning BRISTOL MYERS SQUIBB

305 stories

Jul 20, 26Bristol Myers, Nvidia say they'll build 'most powerful' AI supercomputer in pharmaendpoints

Jul 20, 26STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputerstat

Jul 20, 26BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’fiercebiotech

Jul 20, 26How Kyverna rode CAR T’s autoimmune wave to the FDA’s doorbiospace

Jul 17, 26BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsfiercebiotech

Jul 16, 26Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunobiospace

Jul 16, 26Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 updatefiercebiotech

Jul 16, 26Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialfiercebiotech

Jul 16, 26Opinion: The growing fang-to-pharmacy pipelinestat

Jul 15, 26Braveheart, Attovia join next wave of biotech IPOsbiopharma dive

Jul 13, 26Agenus surges on study pivot; Apnimed lines up an IPObiopharma dive

Jul 6, 26Bristol Myers details Krazati confirmatory study failure in colorectal cancerendpoints

Jul 2, 26A PureTech startup banks $180M for a new IPF drugbiopharma dive

Jul 2, 26Roche KRAS drug succeeds in head-to-head lung cancer studybiopharma dive

Jul 2, 26Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 studyendpoints

Jul 1, 26Abivax shares surge as worries subside over immune drug’s cancer riskbiopharma dive

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 30, 26Beeline ups its Series A round for immune drug workbiopharma dive

Jun 30, 26Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myersendpoints

Jun 30, 26House China panel probes Bristol Myers, Pfizer on use of trial sitesendpoints

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 26, 26At BIO, tension over China biotech deal regulation loomsbiopharma dive

Jun 18, 26cAMPfield lands $180M to build gut disease drugbiopharma dive

Jun 18, 26Kardigan extends biotech’s streak of big IPOs with $400M haulbiopharma dive

Jun 16, 26Edgewise heart drug passes key trial testbiopharma dive

Jun 16, 26Neumora depression drug fails; EnGene to cut 50% of staffbiopharma dive

Jun 15, 26Medicare drug price rule may target under-the-skin Keytruda and Opdivobiopharma dive

Jun 11, 26STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&Astat

Jun 11, 26Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3endpoints

Jun 11, 26Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testbiopharma dive

← prevpage 9 of 11next →